Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapii Uczulen — Clinical Trial Site

39 Registered trials

12 Currently recruiting

Organisation

Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapii Uczulen

Location

Poznan, Poland

Identifier

ORG-100033122

Address

Ul. Tomasza Drobnika 49, 60-693, Poland

Departments

#5754: Allergology
9503
Alergologia Plus Sp. zo.o Osrodek Diagnostyki i Terapii
N/A
NA
Ośrodek Alergologia Plus
Osrodek Diagnostyki i Terapii
Ośrodek Diagnostyki i Terapii Uczuleń
SNZOZ "Alergologia Plus" Ośrodek Diagnostyki i Terapii Uczuleń
SNZOZ Ośrodek Diagnostyki i Terapii Uczuleń Alergologia Plus
Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapi
Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapii
Specjalistyczny Niepubliczny Zakład Opieki Zdrowotnej „ALERGOLOGIA PLUS” Ośrodek Diagn
Specjalistyczny Niepubliczny Zakład Opieki Zdrowotnej Alergologia Plus
Specjalistyczny NZOZ Alergologia Plus Osrodek Diagnostyki I Terapii Uczulen

Clinical trials at this site (39)

Search interface

An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation

2024-510810-33-00 Severe eosinophilic asthma 5 2024-10-14
An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending

2025-522983-33-00 Chronic rhinosinusitis with nasal polyps 5
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending

2025-524078-40-00 Chronic Spontaneous Urticaria 5
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting

2025-523180-38-00 Uncontrolled Moderate to Severe Eosinophilic Asthma 4 2026-05-21
Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting

2025-522896-27-00 Asthma 4 2026-05-11
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm… Recruiting

2025-521268-37-00 Respiratory tract diseases 6 2025-11-25
A Phase 2 Study of Lesigercept (YH35324) in Adult Patients with Chronic Spontaneous Urticaria (CLEAR) Recruiting

2025-524006-14-00 Chronic Spontaneous Urticaria 4 2026-04-20
A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma Recruiting

2025-522640-41-00 Asthma 4 2026-02-13
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-to-Severe Asthma Recruiting

2024-517866-40-00 Moderate-to-severe Asthma 4 2025-09-29
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting

2025-520473-40-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 4 2025-09-29
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona… Recruiting

2024-517458-90-00 Chronic obstructive pulmonary disease (COPD) 5 2025-06-06
Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting

2024-513959-33-00 Asthma 4 2025-05-13
This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting

2023-504713-76-00 Dermatitis atopic 5 2024-12-03
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… Recruiting

2023-508760-29-00 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) 5 2024-10-21
Long-term safety and efficacy evaluation of lunsekimig in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who comp… Ended

2024-515912-27-00 Chronic rhinosinusitis with nasal polyps 4 2025-12-08
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516815-26-00 Chronic rhinosinusitis with nasal polyps 5 2025-05-30
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A Proof of Concept study to assess the efficacy, safety and tolerability of itepekimab (antiIL33 mAb) in participants with chronic rhinosi… Ended

2024-515576-12-00 Respiratory tract diseases 4 2025-03-20
A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Ended

2023-508039-29-00 Moderate-to-severe Asthma 4 2024-09-16
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed trea… Ended

2023-503385-24-00 Asthma 4 2024-03-12
An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr… Ended

2024-510818-33-00 Chronic Spontaneous Urticaria 5 2023-01-24
A proof-of-concept study of lunsekimig compared with placebo in adults with chronic rhinosinusitis with nasal polyps Ended

2024-511261-11-00 Respiratory tract diseases 4 2025-03-05